10 Feb 2009 16:28
Director's Dealings
PuriCore Director Acquires Shares in the Company
MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 10 February 2009 - PuriCore (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today announces that on 9 February 2009 the following Director purchased shares in the Company, as set out below:
| Name
| Number of shares purchased | Purchase Price of shares | Total number of shares held | % of issued share capital |
| Gregory Bosch, CEO | 200,000 | 7.08 p | 800,000 | 0.37 |
Enquiries:
| Ben Brewerton | Greg Bosch, CEO |
| Susan Quigley | Darren Weiss, VP, Finance |
| Financial Dynamics | PuriCore |
| +44 (0) 20 7831 3113 | +1 484 321 2700 |
About PuriCore
PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens. PuriCore targets markets that depend upon controlling contamination, including food safety in retail and foodservice, medical device disinfection, and wound therapy. The Company's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores, simply from water, common salt, and electricity. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of M. tuberculosis, MRSA, E.coli, Norovirus, H5N1 Avian Influenza, HIV, Salmonella, Polio Virus, Helicobater pylori, and Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.
To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.
To subscribe to our investor news alerts, visit http://investor.puricore.com.